Subventions et des contributions :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2018-2019)

Production of vaccine product formulation requires large investments before their commercialization. Successx000D
in these endeavours results in investment returns for the companies producing them and large impact onx000D
population health and longevity. Most vaccine produced today are targeting more than one virus. Thex000D
formulation is complex and involves the addition of adjuvants that are substances that are shown to boost ourx000D
response to a given vaccine drug. In this context, some vaccines do not display the expected immune response.x000D
This maybe linked to the extend of antigens adsorption on the adjuvant, which was shown to be linked to ax000D
vaccine immunogenicity. In this project we are interested in the characterization of the adjuvant morphologyx000D
and surface chemistry and to link this to its ability to adsorbed antigens. This information would allow to assessx000D
how reproducible is the adjuvant surface and to explore ways to tailor its surface chemistry to ensure optimumx000D
adjuvant performances. In this work we will use x-ray photoelectron spectroscopy, Raman and FTIRx000D
spectroscopy, as well as scanning electron microscopy to understand the state of the adjuvant surface underx000D
different conditions. Various activation process as well as chemical treatments will be use to modify thex000D
adjuvant surface and monitor its adsorption properties toward selected antigens. The ultimate goal is to developx000D
a methodology to perform relevant quality control on the produced adjuvant prior to its use in vaccinex000D
formulation.